What do novel diabetes drugs add to CV risk reduction?
Prof. Naveed Sattar, Glasgow, UK provides his view on the potential role of novel diabetes drugs, such as incretin-based therapies, i.e., the DPP-4 inhibitors and GLP-1 receptor agonists or the SGLT2 inhibitors in CV risk management as now 18 randomized clinical trials are going on involving 170.000 patients worldwide to answer this question.
Prof Sattar is Professor of Metabolic Medicine at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, Scotland, UK
View the presentation of Prof. Naveed Sattar:
Slides • 8-9-2014
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.